Dr. Blackwell Discusses the HER2CLIMB Study in HER2+ Breast Cancer

Kimberly L. Blackwell, MD
Published: Tuesday, Mar 06, 2018



Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the HER2CLIMB study in patients with HER2-positive breast cancer.

The HER2CLIMB trial is currently investigating tucatinib (ONT-380), a novel small molecule HER2 inhibitor, in a triplet regimen (NCT02614794). Tucatinib may have the ability to penetrate the blood-brain barrier, making it a potentially beneficial option for patients with HER2-positive breast cancer who have developed brain metastases. In the study, tucatinib and trastuzumab (Herceptin) were combined with capecitabine in patients with unresectable locally advanced or metastatic HER2-positive disease with or without brain metastases.

Blackwell says that the findings of this study may provide efficacy information on whether tucatinib, as a small molecule inhibitor, might prevent progression of brain metastases when added to the regimen of capecitabine and trastuzumab.


Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the HER2CLIMB study in patients with HER2-positive breast cancer.

The HER2CLIMB trial is currently investigating tucatinib (ONT-380), a novel small molecule HER2 inhibitor, in a triplet regimen (NCT02614794). Tucatinib may have the ability to penetrate the blood-brain barrier, making it a potentially beneficial option for patients with HER2-positive breast cancer who have developed brain metastases. In the study, tucatinib and trastuzumab (Herceptin) were combined with capecitabine in patients with unresectable locally advanced or metastatic HER2-positive disease with or without brain metastases.

Blackwell says that the findings of this study may provide efficacy information on whether tucatinib, as a small molecule inhibitor, might prevent progression of brain metastases when added to the regimen of capecitabine and trastuzumab.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x